Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Estudos http://aformulabr.com.br/qrcode/hicaafv01.pdf HICA Hipertrofia com rápida recuperação pós treino DESCRIÇÃO HICA composto por 99% ácido lêucico (ácido alfa-hidroxi-isocapróico), é um metabólito natural do aminoácido leucina, denominado quimicamente como DL ácido alfa hidroxi isocaproico cálcio ou ácido lêucico ou DL-2-hidroxi-4metillvalerico ácido. MECANISMO DE AÇÃO A hipertrofia acontece quando há um balanço proteico positivo, ou seja, a proteólise. A ação do HICA não está envolvida com o anabolismo, mas atuando como um agente catabólico, na inibição da ação de enzimas que degradam proteínas. Assim o efeito anabólico obtido com o seu uso, se dá através de sua contribuição para um balanço proteico positivo, apresentando maior eficiência do que a leucina, já que é o resultado da sua metabolização, permitindo assim maior velocidade na biodisponibilidade tendo o mecanismo anti-catabólico sustentado em experimento in vitro, onde ele inibe a ação de enzimas que degradam as proteínas. O efeito HICA é potencializado com a insulina através da via de sinalização fosfoinositol 3-quinase. A ativação de mTOR resulta na fosforilação da proteína ribossomal S6 quinase (S6K1) e do fator de iniciação da síntese proteica. Diferente de pró- hormonais ou anabolizantes, HICA ativa o anabolismo e o anti-catabolismo sem afetar diretamente os hormônios, estimula o crescimento muscular sem os efeitos contrários dos esteroides. A redução da dor muscular após 4 semanas ingerindo HICA foi considerada uma consequência da inibição de algumas enzimas que são parcialmente responsáveis pela dor muscular, também notando uma maior atenção ao treino a partir da segunda semana do estudo, que pode ter ocorrido porque, como há menos dor muscular, é possível focar mais no treino. INDICAÇÕES Ganho de massa muscular e força; Redução da dor muscular pós treino; acelerar recuperação pós treino; aumento da performance de atletas; Anticatabólico. DOSE USUAL Recomendação oral de 500mg por dose, até 3 vezes ao dia de HICA, ou 1 dose diária, após termino do treino com estômago vazio. SUGESTÕES DE FÓRMULAS HICA...................................................................500mg Pastilhas qsp ......................................................... 1un Modo de uso: 1 dose até 3 vezes ao dia. Recomenda-se o uso de uma das doses, após o término do treino. Indicação: Ganho de massa muscular e força. Beta-alanina...................................................... 400mg L citrulina malato...............................................1000mg Ginseng coreano (Panax ginseng >10% ginsenosídeo ext. seco)……………………………………………..50-100mg HMB................................................................. 1000mg HICA ..................................................................500mg Cafeína anidra....................................................200mg Modo de uso: 1 dose ao dia, após término do treino. Indicação: Estimular o crescimento muscular. PRINCIPAIS REFERÊNCIAS BATISTUZZO, J. A O; ITAYA, M.; ETO, Y. Formulário Médico-Farmacêutico. 5° ed. São Paulo: Pharmabooks, 2015. MERO, A.A. et. al. Effects of alfa-hydroxy-isocaproic acid on body composition, DOMS and performance in athletes. J Int Soc Sports Nutr. V. 7, n. 1, Jan 2010. Disponível em: < http://www.ncbi.nlm.nih.gov/pubmed/?term=alfa-hydroxy-isocaproic+muscle++hica>. Acesso em: 19 de novembro de 2015, às 14:46. HICA ESTUDOS CLÍNICOS Chronic α-hydroxyisocaproic acid treatment improves muscle recovery after immobilization-induced atrophy. Muscle disuse atrophy is observed routinely in patients recovering from traumatic injury and can be either generalized resulting from extended bed rest or localized resulting from single-limb immobilization. The present study addressed the hypothesis that a diet containing 5% α-hydroxyisocaproic acid (α-HICA), a leucine (Leu) metabolite, will slow the loss and/or improve recovery of muscle mass in response to disuse. Adult 14-wk-old male Wistar rats were provided a control diet or an isonitrogenous isocaloric diet containing either 5% α-HICA or Leu. Disuse atrophy was produced by unilateral hindlimb immobilization ("casting") for 7 days and the contralateral muscle used as control. Rats were also casted for 7 days and permitted to recover for 7 or 14 days. Casting decreased gastrocnemius mass, which was associated with both a reduction in protein synthesis and S6K1 phosphorylation as well as enhanced proteasome activity and increased atrogin-1 and MuRF1 mRNA. Although neither α-HICA nor Leu prevented the castinginduced muscle atrophy, the decreased muscle protein synthesis was not observed in α-HICA-treated rats. Neither αHICA nor Leu altered the increased proteasome activity and atrogene expression observed with immobilization. After 14 days of recovery, muscle mass had returned to control values only in the rats fed α-HICA, and this was associated with a sustained increase in protein synthesis and phosphorylation of S6K1 and 4E-BP1 of previously immobilized muscle. Proteasome activity and atrogene mRNA content were at control levels after 14 days and not affected by either treatment. These data suggest that whereas α-HICA does not slow the loss of muscle produced by disuse, it does speed recovery at least in part by maintaining an increased rate of protein synthesis. Effects of alfa-hydroxy-isocaproic acid on body composition, DOMS and performance in athletes. BACKGROUND: Alfa-Hydroxy-isocaproic acid (HICA) is an end product of leucine metabolism in human tissues such as muscle and connective tissue. According to the clinical and experimental studies, HICA can be considered as an anti-catabolic substance. The present study investigated the effects of HICA supplementation on body composition, delayed onset of muscle soreness (DOMS) and physical performance of athletes during a training period.METHODS:Fifteen healthy male soccer players (age 22.1+/-3.9 yr) volunteered for the 4-week double-blind study during an intensive training period. The subjects in the group HICA (n = 8) received 583 mg of sodium salt of HICA (corresponding 500 mg of HICA) mixed with liquid three times a day for 4 weeks, and those in the group PLACEBO (n = 7) received 650 mg of maltodextrin mixed with liquid three times a day for the same period. According to a weekly training schedule, they practiced soccer 3 - 4 times a week, had strength training 1 - 2 times a week, and had one soccer game during the study. The subjects were required to keep diaries on training, nutrition, and symptoms of DOMS. Body composition was evaluated with a dual-energy X-ray absorptiometry (DXA) before and after the 4-week period. Muscle strength and running velocity were measured with field tests.RESULTS:As compared to placebo, the HICA supplementation increased significantly body weight (p < 0.005) and whole lean body mass (p < 0.05) while fat mass remained constant. The lean body mass of lower extremities increased by 400 g in HICA but decreased by 150 g in PLACEBO during the study. This difference between the groups was significant (p < 0.01). The HICA supplementation decreased the whole body DOMS symptoms in the 4(th )week of the treatment (p < 0.05) when compared to placebo. Muscle strength and running velocity did not differ between the groups.CONCLUSION:Already a 4-week HICA supplementation of 1.5 g a day leads to small increases in muscle mass during an intensive training period in soccer athletes. REFERÊNCIAS LANG, C.H. et. al. Chronic α-hydroxyisocaproic acid treatment improves muscle recovery after immobilization-induced atrophy. Am J Physiol Endocrinol Metab. V. 305, n. 3, Aug 2013. Disponível em:< http://www.ncbi.nlm.nih.gov/pubmed/23757407>. Acesso em: 19 de novembro de 2015, às 14:33. MERO, A.A. et. al. Effects of alfa-hydroxy-isocaproic acid on body composition, DOMS and performance in athletes. J Int Soc Sports Nutr. V. 7, n. 1, Jan 2010. Disponível em: < http://www.ncbi.nlm.nih.gov/pubmed/?term=alfa-hydroxy-isocaproic+muscle++hica>. Acesso em: 19 de novembro de 2015, às 14:46.